Multiple sclerosis: Neuroimmune crosstalk and therapeutic targeting

Marc Charabati; Michael A Wheeler; Howard L Weiner; Francisco J Quintana

doi:10.1016/j.cell.2023.03.008

Multiple sclerosis: Neuroimmune crosstalk and therapeutic targeting

Cell. 2023 Mar 30;186(7):1309-1327. doi: 10.1016/j.cell.2023.03.008.

Authors

Marc Charabati¹, Michael A Wheeler², Howard L Weiner¹, Francisco J Quintana³

Affiliations

¹ Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.
² Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
³ Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA. Electronic address: fquintana@rics.bwh.harvard.edu.

Abstract

Multiple sclerosis (MS) is a chronic inflammatory and degenerative disease of the central nervous system afflicting nearly three million individuals worldwide. Neuroimmune interactions between glial, neural, and immune cells play important roles in MS pathology and offer potential targets for therapeutic intervention. Here, we review underlying risk factors, mechanisms of MS pathogenesis, available disease modifying therapies, and examine the value of emerging technologies, which may address unmet clinical needs and identify novel therapeutic targets.

Keywords: B cells; T cells; astrocytes; autoimmunity; glia; microglia; multiple sclerosis; neuroimmunology; progressive MS.

Publication types

Review
Research Support, Non-U.S. Gov't
Research Support, N.I.H., Extramural

MeSH terms

Cell Physiological Phenomena
Central Nervous System
Humans
Inflammation / pathology
Multiple Sclerosis* / drug therapy
Neuroglia

Abstract

Publication types

MeSH terms

Grants and funding